BridgeMD
New treatment option for Juvenile Idiopathic Arthritis (JIA)
Official title OLE Study With Filgotinib in JIA
ClinicalTrials.gov ID: NCT07553182
What this study is testing
What is Filgotinib?
Filgotinib is an investigational medicine, given as an once-daily pill taken by mouth, being studied as a potential treatment for juvenile idiopathic arthritis (jia).
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This OLE study is designed to evaluate long-term safety, tolerability, and efficacy of filgotinib in patients with polyarticular or systemic juvenile idiopathic arthritis (pJIA-sJIA) who have completed the treatment period/prolonged treatment period of the parent studies and demonstrated clinical benefit defined as control of disease activity through improvement in signs and symptoms as per Investigator judgement.
- Phase 3: a large, late-stage study
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 8 to 18
You may be able to join if
- Subject must have completed treatment with filgotinib in at least one parent study and achieved a clinical benefit at the end of the parent protocols
- Subject and/or parent/legal guardian must be able and willing to comply with the clinical study protocol requirements and must sign and date the...
- Female or male subject 8 to \<18 years of age, on the date of signing the informed consent and assent (per local regulation) form
- Female subject of childbearing potential who is sexually active and at risk for pregnancy must agree to use contraception/preventive exposure...
You likely can't join if
- Development of any condition during the parent study that would preclude safe continuation
- Pregnancy
- Active infection that is clinically significant, as per Investigator's judgement
- Subject with known hypersensitivity to the components of potential study therapy
- people with any condition or circumstances (including abnormalities in laboratory parameters) that, in the opinion of the investigator, may make a...
The study team makes the final eligibility decision.
Where it's taking place
- Le Kremlin-Bicêtre, France
- Hamburg, Germany
- Sankt Augustin, Germany
- London, United Kingdom
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 8 years to 18 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Le Kremlin-Bicêtre, France; Hamburg, Germany; Sankt Augustin, Germany; London, United Kingdom. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.